Welcome to our dedicated news page for Lucid Diagnostics (Ticker: LUCD), a resource for investors and traders seeking the latest updates and insights on Lucid Diagnostics.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lucid Diagnostics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lucid Diagnostics's position in the market.
Rhea-AI Summary
Lucid Diagnostics Inc. highlights EsoCheck's advanced cell collection technology during testimony before the U.S. House of Representatives' Committee on Small Business. EsoCheck's innovative Collect & Protect® technology offers precise, noninvasive esophageal cell collection, leading to unprecedented early precancer detection results. The device's efficiency allows for high-volume testing events, with excellent patient satisfaction and DNA yields. In contrast, older 'sponge-on-a-string' technologies lack EsoCheck's precision and protection features, resulting in poor sensitivity and mechanical failures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
-
Rhea-AI Summary
Lucid Diagnostics Inc. announces a contract with the World Trade Center Health Program to provide EsoGuard Esophageal DNA test as a covered benefit to more than 120,000 responders and survivors of the 9/11 terrorist attacks. The test is reimbursable at $2,475.81 per test prescribed by clinicians at WTCHP's Clinical Centers of Excellence. This initiative aims to expand patient access to EsoGuard testing and prevent esophageal cancer and cancer deaths.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
-
Rhea-AI Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD) has announced the publication of three clinical utility studies demonstrating the real-world clinical utility of Lucid's EsoGuard Esophageal DNA test to detect esophageal precancer. The studies document near-perfect concordance between EsoGuard results and the prescribing physician's decision whether to refer patients for upper endoscopy, with 100 percent of EsoGuard-positive patients being referred for confirmatory upper endoscopy. These results eliminate the need for hundreds of costly, invasive, and inconvenient endoscopies, demonstrating that EsoGuard allows physicians to appropriately triage at-risk patients, consistent with established professional society guidelines, and ensure cost-effective utilization of endoscopy in esophageal precancer detection.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
Rhea-AI Summary
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announces the distribution of approximately 3.3 million shares of Lucid common stock to its shareholders as of January 15, 2024. Each PAVmed shareholder will receive a stock dividend of approximately 41 shares of Lucid common stock for every 100 shares of PAVmed common stock they own as of the record date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announces a dividend of approximately 3.3 million shares of Lucid Diagnostics Inc. (Nasdaq: LUCD) common stock and a 1-for-15 reverse stock split to be effective as of market open on December 7, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.55%
Tags
-
Rhea-AI Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD) strengthens its executive team with two industry veterans, Natalie S. Carfora and James M. Fricchione, joining as Vice President, Market Access, and Vice President, Employer Markets, respectively. Shaun M. O'Neil is promoted to President and COO. These appointments aim to drive EsoGuard® payor coverage and secure direct contracts with employers and self-insured entities, crucial for translating test volume growth into revenue. Natalie Carfora brings over a decade of experience in market access and sales, while Jim Fricchione has over two decades of national health benefits experience. Shaun O'Neil, an industry veteran, has been instrumental in designing and building Lucid's commercial infrastructure and overseeing its commercial strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
Rhea-AI Summary
PAVmed Inc. (NASDAQ: PAVM, PAVMZ) reported a 392% sequential increase in Lucid's quarterly revenue, with Veris Health's expansion efforts underway. The quarterly financial results were presented, and a webcast is scheduled for tomorrow at 8:30 AM EST.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
-
Rhea-AI Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD) reports a 17% increase in Quarterly EsoGuard® test volume and a 392% increase in revenue sequentially. The company's CLIA-certified clinical laboratory performed 2,575 commercial EsoGuard® Esophageal DNA Tests in Q3 2023. Lucid's Q3 revenue was $783K, with operating expenses of $11.9 million. Lucid had cash and cash equivalents of $24.1 million as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.07%
Tags
-
Rhea-AI Summary
LUCD - Lucid Diagnostics Inc. (Nasdaq: LUCD) announced the launch of EsoGuard 2.0, an enhanced esophageal DNA test with improved performance and lower costs. The company will also host an Investor Day event in New York City on December 13, 2023, to discuss commercial progress and the recent expansion of clinical utility and validity data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Lucid Diagnostics Inc., a cancer prevention medical diagnostics company, announced that its Chairman and CEO, Dr. Lishan Aklog, will present at the Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum on November 16, 2023, in New York City. The presentation will take place at 10:00am EST, and management will be available for one-on-one meetings with investors at the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
Lucid Diagnostics Inc.
Nasdaq:LUCD
LUCD Rankings
LUCD Stock Data
45.83M
15.07M
70.39%
3.66%
0.91%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
NEW YORK